4 results about "Clot lysis" patented technology

The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and / or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.

Devices and methods for clot bursting pressure measurement are disclosed herein. Particular embodiments include a pump, a pressure measurement device, and a container having an inlet, an outlet, and an orifice. In particular embodiments, a pump is coupled to an inlet of a container, a pressure measurement device is coupled to an outlet of the container, and an orifice is configured to hold fluid extending across the orifice.

The invention relates to an in vitro method for measuring fibrin clot degradation based on a fibrin clot lysis curve over time in a blood or plasma sample previously obtained from a patient suspected of having a deficiency in at least one coagulation factor. This method includes determining a baseline fibrin clot level at time t1 and determining a degraded fibrin clot level at a subsequent time t2. The method may include an additional step of classifying the tested sample into a group reflecting a fibrin clot lysis profile. The invention also relates to a method for monitoring therapeutic treatment administered to a patient suspected of having, or who has, a deficiency in at least one coagulation factor. This method may further include a step of adjusting the patient's therapeutic treatment based on the classification obtained.The invention relates to enclosing the use of tranexamic acid (TXA) or a composition comprising it for use in a therapeutic treatment, said use comprising the implementation of a method according to the invention, and means for the implementation of the invention.

The application provides a milk protein source urokinase-type plasminogen activator inhibitory peptide and application thereof. Through a combination of virtual screening by molecular docking and in-vitro experiment verification, two u-PA inhibitory activity polypeptides PEVMGVSK and HIQKEDVPSE derived from bovine milk casein are obtained. The two polypeptides can be stably combined with the u-PA active site through multiple intermolecular forces, have a significant inhibitory effect on u-PA-mediated plasminogen activation, can effectively improve the storage period stability of ultra-high temperature instant sterilized milk, delay protein hydrolysis and aging gel formation, and can inhibit the plasmin clot lysis and MDA-MB-231 human breast cancer cell migration in a concentration-dependent manner. The polypeptides obtained by the application have application potential and practical value in the fields of dairy product quality improvement, hemostatic drugs and anti-cancer drug research, etc. as natural source active ingredients.